Figures computed from official regulatory filings — .
Analysttarget 174.69 USD (+25%) · consensus 4.77/5 · 13 buy · 0 hold · 0 sell
Ownershipinsiders 0.71% · institutions 119.64% · short 14.6% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Protagonist Therapeutics, Inc only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
13 buys126 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Ali Asif | Exercise | $359.7K | Unusual size | SEC |
| Ali Asif | Exercise | $64.6K | SEC |
| Ali Asif | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ali Asif | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ali Asif | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ali Asif | Exercise | $666K | Unusual size | SEC |
| Ali Asif | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ali Asif | Sell | $1.8M | SEC |
| Ali Asif | Exercise | $300.3K | SEC |
| PATEL DINESH V PH D | Sell | $9.3M | Unusual size | SEC |
| PATEL DINESH V PH D | Exercise | $1.4M | Unusual size | SEC |
| PATEL DINESH V PH D | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| PATEL DINESH V PH D | Exercise | $1.2M | SEC |
| PATEL DINESH V PH D | Sell | $1M | SEC |
| PATEL DINESH V PH D | Exercise | $157.1K | SEC |
| PATEL DINESH V PH D | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| PATEL DINESH V PH D | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| PATEL DINESH V PH D | Sell | $7.9M | Unusual size | SEC |
| PATEL DINESH V PH D | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| PATEL DINESH V PH D | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| PATEL DINESH V PH D | Exercise | $1.4M | Unusual size | SEC |
| PATEL DINESH V PH D | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| PATEL DINESH V PH D | Exercise | $738.9K | SEC |
| PATEL DINESH V PH D | Sell | $9.8M | Unusual size | SEC |